Grasin (filgrastim biosimilar) / Jeil, Kyowa Kirin - LARVOL DELTA

[VIRTUAL] Automated Hematopoietic Progenitor Cell Analysis in Clinical Management of Peripheral Blood Stem Cell Collections (ICBMT 2021) - "Conclusion : HPC count correlates with CD34+ count, which suggests HPC can be used to predict CD34+ level. Etoposide usage did not show significant increase in collected CD34+."

Clinical • Hematological Disorders • Solid Tumor • Transplantation • CD34

Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data. (PubMed, Toxicol Appl Pharmacol) - "Filgrastim, a biopharmaceutical listed on WHO model list of essential medicines, was approved in USA in 1991 for patients with non-myeloid malignancies associated with severe neutropenia and fever...Overall, 11,183 adverse drugs reaction reports were identified during observation period; of which 5764; 51.5% reports concerned to Neupogen®, the originator, and rest consists of Leucostim® (N = 680), Zarzio® (N = 622), Grasin® (N = 545), Nivestim® (N = 359) and Tevagrastim® (N = 152) biosimilars...Authors observed significant differences among originator and biosimilars in particular to efficacy, adverse events reported and time to onset of occurrences. Large epidemiologic studies are needed to further confirm these finding and provide additional insights."

Journal • Back Pain • Hematological Disorders • Musculoskeletal Pain • Neutropenia • Oncology • Pain